Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129328 | 0.97 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2743225 | 0.94 | — | — | |
| SCHEMBL9944706 | 0.88 | — | — | |
| SCHEMBL2761539 | 0.79 | SLC6A4 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2761898 | 0.79 | SLC6A4 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL23570011 | 0.76 | — | — | |
| SCHEMBL13900941 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL30911735 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL30911818 | 0.74 | — | — | |
| SCHEMBL23555032 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-1106614-B1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | SLC6A3 2706/4885SLC6A4 1053/4885SLC6A2 3471/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | SLC6A3 2706/4885SLC6A4 1053/4885SLC6A2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.